Mineralys Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Mineralys Therapeutics, Inc. income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Revenue & Gross Profit
Revenue0.000.000.000.000.00
Cost of Revenue0.040.000.000.000.00
Gross Profit-0.040.000.000.000.00
Operating Expenses
Research & Development168.5870.3626.2516.312.41
Selling, General & Administrative23.8214.305.232.420.53
Operating Expenses192.4084.6631.4818.732.94
Operating Income-192.40-84.66-31.48-18.73-2.94
Other Income/Expense
Interest Income14.5912.761.680.000.00
Interest Expense0.000.000.000.03-0.12
Other Income/Expense0.010.000.00-0.66-0.37
Income
Income Before Tax-177.81-71.90-29.80-19.41-3.43
Income Tax Expense0.000.000.000.000.00
Net Income-177.81-71.90-29.80-19.41-3.43
Net Income - Continuous Operations-177.81-71.90-29.80-19.410.00
Net Income - Discontinued Operations0.000.000.000.000.00
EBITDA-192.36-71.90-31.48-19.380.00
EBIT-192.40-84.66-31.48-19.38-2.94
Depreciation & Amortization0.040.000.000.000.00
Earnings Per Share
Basic EPS-4.00-2.00-6.00-4.00-1.00
Diluted EPS-4.00-2.00-6.00-4.00-1.00
Basic Shares Outstanding48.5436.195.175.154.63
Diluted Shares Outstanding48.5436.195.175.154.63